Home Page
 
Skip navigation links
Home
About Us
Business Assistance
Funding
News & Events
Facts & Maps
Resources
Skip Navigation LinksMaryland Biotechnology Center > News Events

News Archive  

Maryland Industry News: 2009 

 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

January

Biotech firm lands $2.1M funding
Baltimore Business Journal
A biotechnology firm in East Baltimore has raised $2.1 million of a $10 million equity offering, according to a regulatory filing with the Securities and Exchange Commission.  Read More...


Biofuel startup to expand production in Baltimore
Baltimore Sun
A biofuel startup with a Baltimore production plant is planning to expand and hire this year, as orders for its cleaner-burning fuel grow, according to the firm's chief executive officer. Read More....

Bioactive Surgical Inc.
Baltimore Business Journal
Rick Spedden’s surgery to fix his ruptured Achilles tendon left him in some pain. But it also left him with a business partner and a burgeoning company. 
Read More....

Fyodor Biotechnologies Corp.
Baltimore Business Journal
As a child growing up in Nigeria, Eddy C. Agbo saw first hand the devastating effects of malaria.
Read More....

Claire M. Fraser-Liggett, Institute for Genome Sciences
Washington Post
In my senior year of college, I did research with a doctor that got me excited about what a career in medical research was all about. 
Read More...


December
 

BioElectronics Ends 2009 with International Product and Partner Gains
Yahoo Finance
BioElectronics Corp.,
the maker of inexpensive, disposable, drug-free anti-inflammatory devices, announced product gains in the international market as well as new international distributor and marketing partnerships. As a result, BioElectronics is expecting significant gains in international markets throughout 2010.  Read More...

MEDIFACTS INTERNATIONAL Drives Innovation in Telemedicine for Clinical Trials
Business Wire
MEDIFACTS INTERNATIONAL, INC. announced their new innovation in the use of telemedicine, T-SMBP (Telemonitoring Self Measured Blood Pressure), is in clinical trials. T-SMBP allows for remote collection of blood pressure (BP) data from a subject’s home.  Read More...

Celsion Announces Treatment of First Patient in China in Global Phase III ThermoDox(R) Trial for Primary Liver Cancer
Press Release
Celsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion's global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.  Read More...

Rexahn and TheraTarget Form Nano Science Research Collaboration
Business Wire
Rexahn Pharmaceuticals, Inc. and TheraTarget, Inc. announced the formation of a joint research collaboration agreement. Under the terms of the agreement, TheraTarget will synthesize and supply Rexahn with polymer-drug conjugate products, which are part of Rexahn’s polymer-based nanomedicine portfolio.  Read More...

MedImmune responds to FDA on pediatric drug
Washington Business Journal
AstraZeneca PLC
, the London pharmaceutical that owns MedImmune, said the local subsidiary has filed its formal responses to the Food and Drug Administration’s questions about motavizumab, an enhanced version of MedImmune’s blockbuster drug Synagis for the prevention of respiratory syncytial virus disease in infants.  Read More...

HGSI competitor Elusys scores federal contract
Washington Business Journal
A U.S. Health and Human Services agency has awarded an up to $143 million contract to further develop an inhaled anthrax treatment that could rival a similar product at Rockville-based Human Genome Sciences Inc.
Read More...

HGSI jumps on stock recommendation
Washington Business Journal
Shares of Human Genome Sciences Inc. rose $1.41, or 5 percent, to $29.58 Monday after Morgan Stanley initiated new coverage of the Rockville drug maker with a rating of "overweight."  Read More...

MedImmune Recalling Swine Flu Vaccine
Reuters
MedImmune is voluntarily recalling some of its H1N1 swine flu vaccine because it was not as potent as it should be.  Read More...

Maryland cancer-testing firm MarkPap lands first customer
Washington Post
Nenad and Olivera Markovic labored for years to design a low-cost kit that could be used for the early detection of cervical cancer in women in poor and underdeveloped regions.  Read More...

Human Genome Sciences Announces Submission of Marketing Authorization Application to EMEA for JOULFERON® (ZALBIN™)
Press Release
Human Genome Sciences, Inc. announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. Read More...

Rexahn and TheraTarget Form Nano Science Research Collaboration
Press Release
Rexahn Pharmaceuticals, Inc. and TheraTarget, Inc. announced the formation of a joint research collaboration agreement. Under the terms of the agreement, TheraTarget will synthesize and supply Rexahn with polymer-drug conjugate products, which are part of Rexahn’s polymer-based nanomedicine portfolio. Read More...

Celsion Announces Treatment of First Patient in China in Global Phase III ThermoDox® Trial for Primary Liver Cancer
Press Release
Celsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion's global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Read More...

General Physics Corporations’ Domestic Preparedness Equipment Training Assistance Program (DPETAP) Achieves Major Chemical, Biological, Radiological, and Nuclear Training Milestone
Press Release
General Physics Corporation (GP), a subsidiary of GP Strategies Corporation, announced today it has achieved a major milestone by providing Chemical, Biological, Radiological, and Nuclear (CBRN) detection, protection and decontamination equipment training to over 90,000 first responders.
Read More...

FYI FROM HUMAN GENOME SCIENCES: GSK INITIATES SECOND PIVOTAL PHASE 3 TRIAL FOR INVESTIGATIONAL CARDIOVASCULAR MEDICATION DARAPLADIB
Press Release
GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS). Read More...

RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352
Press Release
RegeneRX has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. Read More...

MedImmune: Collaboration With Trellis Bioscience, Inc. Strengthens RSV Pipeline
BioSpace
MedImmune has agreed to license the rights to develop Trellis Bioscience's monoclonal antibody products for the treatment of respiratory syncytial virus (RSV). Read More...

PharmAthene reports positive early phase results for Protexia
Baltimore Business Journal
Early clinical trials by
PharmAthene Inc. testing a potential treatment for exposure to chemical nerve agents have generated positive results. 
Read More...

Nabi Biopharmaceuticals CEO Raafat Fahim cashes in on deals
Washington Business Journal
Nabi Biopharmaceuticals Inc.
CEO Raafat Fahim got plenty of accolades for his latest win — a deal potentially worth $540 million with GlaxoSmithKline PLC.  Read More...

MiddleBrook Pharmaceuticals, Inc. Reduces Field Sales Force and Corporate Staff, Receives Notice from Nasdaq Regarding Minimum B
FierceBiotech
MiddleBrook Pharmaceuticals, Inc. today announced a reduction of its field sales force and corporate staff. Effective December 4, 2009, MiddleBrook will reduce the number of its sales managers and field sales representatives by about one-third, to approximately 145, and its corporate staff by approximately 20 percent. Read More...

Human Genome Sciences prices its latest stock offering
Baltimore Business Journal
Human Genome Sciences Inc.
has priced its shares at $26.75 apiece, a less than 3 percent discount from Wednesday’s closing price, for its second major stock offering in four months. Read More...

PharmAthene Presents rPA Anthrax Vaccine Data
PRNewswire
New Data Shows PharmAthene's Lyophilized rPA Anthrax Vaccine Could Provide a Stable Cold-Chain-Free Vaccine for Potential Storage and Distribution at Room Temperature.  Read More

Trellis Bioscience, Inc. Grants MedImmune License for Its Anti-RSV Antibodies in Deal Worth Potentially $338 Million
BioSpace
Trellis Bioscience, Inc. announced today the granting of a worldwide exclusive license to MedImmune, LLC, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV). Read More

November

HGS seeks Zalbin OK as analysts revive buyout buzz
FierceBiotech
Human Genome Sciences has filed for FDA approval of its promising hepatitis C drug Zalbin. Read More

Earnings-Business Gazette
The Gazette
Rockville biotechnology company Neuralstem showed a third-quarter net loss of $5.1 million. Read More

Qiagen Is Poised for More Purchases After $2 Billion Spree
Bloomberg Press
Qiagen NV
, a company that has spent about $2 billion on acquisitions since 2004, is armed for yet more takeovers as it seeks additional gene-based tools to predict disease. Read More...

FDA requests more details on HGSI anthrax drug
Washington Business Journal
Human Genome Sciences Inc. said federal regulators still need more information before they can approve the Rockville company’s anthrax treatment, delivering a blow in what’s otherwise been a good month for the company. Read More...

Emergent BioSolutions (EBS) Acquires Manufacturing Facility from MdBio, Inc. and Land from City of Baltimore for $8.2 Million
BioSpace
Emergent BioSolutions Inc. announced that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. Read More...


QIAGEN N.V. to Acquire SABiosciences for $90 Million in Cash
BioSpace 
Transaction adds to QIAGEN's content engine for development of future diagnostics and boosts the Company's presence in pharma discovery and validation. Read More... 

Micromet takes back MedImmune's blinatumomab rights
FierceBiotech
Micromet has agreed to buy out MedImmune's North American rights to blinatumomab, a potential treatment for lymphoma and leukemia.
Read More... 

MedImmune vets launch biotech with $10M Series A
FierceBiotech
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million in Series A funding from New Enterprise Associates (NEA). Read More... 

GenVec cancer drug gets orphan status, shares soar
Reuters
FDA grants orphan drug status to TNFerade. Shares up as much as 25 pct. Read More...

Akonni Launches TruTip™ Kits for Rapid Nucleic Acid Extraction
Genetic Engineering & Biotechnology News
Akonni Biosystems, a molecular diagnostic (MDx) company focused on providing rapid and highly scalable solutions for research and infectious disease testing, announced the worldwide launch of their TruTip product line for extracting DNA and RNA from samples with volumes ranging from 100 µl to 1000 µl or more. Read More....

Human Genome Sciences sees positive results for lupus drug
Washington Business Journal
Human Genome Sciences Inc. said its second round of late-stage clinical trials proved positive for its key lupus drug. Read More...

October 

FDA experts want to see more ABthrax data
FierceBiotech
A panel of FDA experts says that Human Genome Sciences should provide more data on how its anthrax drug ABthrax stacks up against the antibiotics already available for treatment. Read More...

HGS hit with anthrax setback
FierceBiotech
In a setback for Human Genome Sciences, the FDA said that questions regarding the human data collected on its anthrax drug made it impossible "to make a complete judgment about whether raxibacumab should be licensed for marketing...." Read More...

Emergent BioSolutions buying Baltimore manufacturing facility
Washington Business Journal
Emergent BioSolutions Inc. is finalizing a deal to purchase a manufacturing facility near Johns Hopkins Bayview Medical Center in Baltimore and could invest $15 million to $20 million in the property. Read More...

SAIC-Frederick fifth in stimulus contracts
The Gazette
The wholly owned subsidiary of Science Applications International Corp. received the fifth most federal contracting dollars under the American Recovery and Reinvestment Act of 2009. Read More...

Biotechs Back From The Dead
Forbes
The financial crisis was supposed to annihilate small companies, but many survived. Read More...

Rexahn Pharmaceuticals to Present at the 8th Annual Bio Investor Forum
SmartBrief
Rexahn Pharmaceuticals will provide a strategic business overview and updates on Rexahn’s recent clinical and financing milestones, opportunities for licensing and alliances and the R&D pipeline.
Read More...

Celsion’s Global Phase III ThermoDox® Trial Approved by SFDA in China
BioSpace
Celsion Corporation announced today that it has received official approval from China’s State Food and Drug Administration (“SFDA”) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).
Read More...

U.S. Patent Issued for
Champions Biotechnology, Inc. (CSBR)'s Lead Oncology Drug
BioSpace
Champions Biotechnology, Inc. today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.
Read More...

Sequella, Inc. Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
BioSpace
Sequella, Inc received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic. Read More...

President of Panacea Pharmaceuticals resigns
Washington Business Journal
Stephen Keith has left his executive post at embattled Panacea Pharmaceuticals Inc. to head the American College of Clinical Pharmacology
. Read More...

Vanda reaps $200M upfront in Novartis drug pact
Fierce Biotech
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia. Read More... 

United BioSource Corporation  Receives $125 Million Growth Equity Investment 

BioSpace
United BioSource Corporation today announced that Berkshire Partners LLC, a Boston-based private equity firm, has made a $125 million growth equity investment to support the Company’s evidence-based acquisition and service offering expansion strategy. Read More... 

Intralytix Wins Army Contract to Develop a Phage-Based Probiotic to Manage Shigella Infections
Business Wire
Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR contract supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections. Read More...


MedImmune set to deliver 'swine flu' vaccines
Washington Business Journal
MedImmune is providing the first lots of H1N1 vaccines to be delivered as early as tomorrow to 47 jurisdictions, including Maryland, Virginia and the District. Read More...

September

Neuralstem wins FDA approval for ALS stem cell trial
Washington Business Journal
Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news. 
Read More...

GenVec out of Nasdaq compliance
Washington Business Journal
The price of stock in
GenVec Inc. has been too low for too long putting the company out of compliance with Nasdaq requirements and threatening the firms listing.  Read More...

Cel-Sci, Novavax to raise $30M
Washington Business Journal
Cel-Sci Corp. and Novavax Inc., both developing swine flu-related products, have each indicated plans to sell stock to raise a combined $30 million in financing, joining other area money-raising biotechs after nearly a yearlong dry spell in the life sciences capital markets.  Read More...

$453M and counting for MedImmune as vaccine order grows
Gazette
MedImmune said Monday it has received a federal order for 29 million more doses of its nasal H1N1 flu vaccine, bringing its total order to more than 40 million doses with a value of about $453 million.  Orders from the Department of Health and Human Services for about 13 million doses of the Gaithersburg biotech's vaccine were placed in May and July. 
Read More...

Intralytix Wins Army Grant To Develop Acinetobacter baumannii (Iraqibacter) Technology
7th Space Interactive
Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a phage-based product for treating wounds infected with Acinetobacter baumannii. Read More...

Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
FierceBiotech
Osiris Therapeutics announced that preliminary results indicate that its stem cell therapy Prochymal failed both of its late-stage clinical trials. Read More...

New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patients
BioSpace
GlycoMimetics, Inc. (GMI), announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients.
Read More...

Novavax reports good results from swine flu vaccine
Washington Business Journal
Novavax Inc. reported positive results from a mid-stage clinical trial of its vaccine technology for three flu strains, including the H1N1 strain more commonly known as the swine flu. Read More...

Novavax is on a roll with mid-stage VLP success
FierceBiotech
Novavax announced this morning that its trivalent seasonal flu vaccine produced the kind of strong immune response against three flu strains--including H1N1. Read More...

August

Rumors: Glaxo eyes bid for Human Genome Sciences
FierceBiotech
The Telegraph reports that rumors are beginning to pop up that GlaxoSmithKline is preparing to make a $30-a-share offer to buy up the newly hot stock of Human Genome Sciences. Read More...

Pandemic offers AstraZeneca a blockbuster return
Fiercebiotech
New report from Jefferies International estimates that the global swine flu windfall will be worth around $2.3 billion in new sales for MedImmune in 2009 and 2010. Read More...

Neuralstem’s compliance plans gets the OK
Washington Business Journal
Neuralstem said its listing compliance plan has been accepted by the Stock Exchange Amex Exchange and was given more than a year to become compliant again. Read More...

Novavax says vaccine works in ferrets
Washington Business Journal
Novavax, which announced its successful creation of an N1H1 vaccine earlier this month, says it has tested the vaccine in ferrets and it works.
Read More...

MedImmune to test swine flu vaccine
Washington Business Journal
MedImmune has begun enrolling volunteers around the country for its first clinical trials to test its swine flu vaccine candidate. Read More...

Innovative Biosensors CEO resigns
Washington Business Journal
Joe Hernandez, the founder, president and CEO of Innovative Biosensors Inc. of Rockville, resigned Aug. 7, the company said late Monday.
Read More... 

Vanda Pharmaceuticals loses $12.4M
Washington Business Journal
Vanda Pharmaceuticals Inc. narrowed its loss during the second quarter as it rushed to land its lead drug on pharmacy shelves later this year.
Read More...

BioWatch: Biotechs tackle flu
Washington Business Journal
Novavax, MedImmune developing vaccines using alternative methods. Read More...

NewsWatch: Emergent to exit Frederick, expand in Gaithersburg
Washington Business Journal
Emergent BioSolutions of Rockville plans to expand its infrastructure while reducing its debts and expenses by selling two facilities in Frederick and buying new manufacturing and laboratory facilities in Gaithersburg.
Read More...

GenVec reports smaller loss
Washington Business Journal
The Gaithersburg-based biotechnology company, working on vaccines for HIV and malaria, had a second quarter net loss of $4.8 million, or 5 cents per share, compared to a net loss of $6.6 million, or 8 cents per share in the same quarter a year ago. Read More...

Sucampo Pharmaceuticals posts quarterly loss
Washington Business Journal
Sucampo Pharmaceuticals Inc. posted a small loss for its latest quarter, on slower sales of its flagship drug. Read More...

Anthrax vaccine propels Emergent sales
Washington Business Journal
The Rockville-based company had second-quarter revenue of $73.2 million, compared with $42.3 million in the same quarter a year ago.
Read More...

Novavax narrows loss
Washington Business Journal
Novavax Inc., which said this week it successfully created a swine flu vaccine, bounced back in the second quarter, narrowing its loss and retiring all of its convertible debt. Read More...

Nabi to sell staph vaccine to Glaxo for $46 mln
Reuters
Nabi Biopharmaceuticals said it agreed to the sell PentaStaph, its experimental vaccine for staph infections and related assets to GlaxoSmithKline Plc for up to $46 million. Read More...

EntreMed cuts losses to $3.1M
Washington Business Journal
After freezing most of its drug research and shrinking its staff since late last year, EntreMed Inc. had cut its expenses enough to slash its second-quarter losses by two-thirds. Read more...

Sales down, losses up for Micromet
Washington Business Journal
Fresh off of reeling in $75 million in a private placement financing, Micromet Inc. reported that it widened its losses by nearly two-thirds in the second quarter this year. Read More...

Novavax rallies on Swine flu breakthrough
Washigton Business Journal
Novavax stock rallied as much as 21 percent in Wednesday trading after the company said it has successfully created a swine flu vaccine.
Read More...

Nabi Biopharmaceuticals looks for buyer
Washington Business Journal
Nabi Biopharmaceuticals has indicated its desire to be acquired, tying its executive bonuses more closely to such a move. Read More...

Human Genome stock sale nets $358M
Washington Business Journal
Human Genome Sciences Inc. raised $357.6 million in its secondary stock offering after the company last week increased the amount of stock it planned to sell.
Read More...

Back to Top

July

United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
Yahoo! Finance
Revenues of $84.0 Million, 22.5% Increase over Second Quarter 2008.
Read More...

Medimmune's Nasal Vaccine Holds Promise Against Swine Flu
New York Times 
As the nation girds for a possible swine flu pandemic, one of the big weapons may come from an unexpected source — a vaccine squirted or dropped into the nose. Read More...

Supernus Pharmaceuticals raises $35M
Washington Business Journal
Supernus Pharmaceuticals Inc. has closed on a more than $35 million financing deal in return for its future royalty payments from an undisclosed partner company. Read More...

Micromet to raise at least $70M
Washington Business Journal
Micromet Inc. intends to raise at least $70 million, and as much as $80 million, in a public stock offering of up to 16.1 million of its shares. Read More...

GenVec Receives Grant for Malaria Vaccine Program
Yahoo!Finance
GenVec, Inc. announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company's malaria vaccine program. Read More...

Sucampo, Takeda drug gets mixed results in studies
Yahoo! Finance
Sucampo Pharmaceuticals Inc. and partner Takeda Pharmaceuticals said Tuesday their drug candidate lubiprostone produced mixed results in two late-stage studies focusing on a condition causing constipation in patients on pain drugs.
Read More...

HGS raising $310M after shares skyrocket
FierceBiotech
Human Genome Sciences plans to raise $310 million from the sale of 18 million common shares. And some of that money may be used to buy or invest in new technology, companies or products. Read More...

Osiris Achieves Milestone Payment for Progress Developing Stem Cell Therapy for Type 1 Diabetes
Business Wire
Osiris Therapeutics, Inc. announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for progress made on a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. Read More...

FluMist(R) Begins Shipping for 2009-2010 Influenza Season
Press Release
MedImmune announced today that it has begun shipping its seasonal influenza vaccine FluMist((R) )(Influenza Vaccine Live, Intranasal) to vaccine distributors who service health care providers throughout the United States. Read More...

Nabi Biopharmaceuticals to Announce 2009 Second Quarter Financial Results on August 6, 2009
GlobalNewswire
Nabi Biopharmaceuticals today announced that it will report its 2009 second quarter financial results on Thursday, August 6, 2009, after market close. The company will host a live webcast at 4:30 p.m. EDT that day to discuss these results. Read More...

Profectus Biosciences lands $5M round of venture capital
Baltimore Business Journal
Profectus BioSciences Inc., an HIV and cancer research company, has secured $5 million in financing from venture firm Cross Atlantic Capital Partners. Read More...

PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 
Press Release
PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has signed definitive agreements for the issuance of 2-year, 10% unsecured senior convertible notes  and common stock purchase warrants in a private placement of approximately $19.3 million. Read More...

Human Genome Science Triples on Success of Lupus Drug
Bloomberg
Human Genome Sciences Inc. more than tripled in New York trading after the company and GlaxoSmithKline Plc said their experimental lupus drug reduced patients’ symptoms in a yearlong study.
Read More...

Martek Marks Major Milestones
Daily Record
European Union approved the use of Martek’s product, life’sDHA, in additional foods. Read More...

MedImmune gets second H1N1 flu contract
Washington Business Journal
The U.S. Department of Health and Human Services has awarded MedImmune with additional $61 million  contract to test its nasal spray flu technology as a viable treatment for the new virus. Read More...

Rexahn Pharmaceuticals regains listing compliance
Washington Business Journal
Rexahn has regained compliance with the requirements of the NYSE Amex Company Guide for the continued listing of its common stock on the Exchange. Read More...

Neuralstem raises $1M from stock sale
Washington Business Journal
Neuralstem  will use Vicis Capital Master Fund's investment to push forward its human spinal cord neural stem cell treatment. Read More...

                                                                                                           Back to Top

June

GenVec cuts manufacturing partnership
Washington Business Review
Genvec has terminated its manufacturing partnership with Cobra Biomanufacturing Plc for the manufacturing of their anticancer treatment TNFerade.
Read More...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTÉGÉ, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Press Release
MacroGenics, Inc. and Eli Lilly and Company today announced that the PROTÉGÉ trial achieved its targeted patient enrollment.  The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes. 
Read More...

Novavax stock soars on license deal
Washington Business Journal
Novavax Inc. it’s negotiating a multimillion-dollar deal to license out its flu-vaccine-making technology to a Spanish pharmaceutical Rovi Pharmaceuticals Laboratories. Read More...

Rockville-based Emergent gets boost from regulator
The Gazette
Food and Drug Administration approved extending the shelf life of Emergent's anthrax vaccine from three to four years. Read More...

Novavax surges on swine flu vaccine
Washington Business Journal
 
Novavax stock surged nearly 50 percent Thursday after the Rockville company said it had succeeded in producing  a swine flu vaccine and the government has agreed to test it. Read More...

Local biotechs search for partners to help them survive
Washington Business Journal
In this economy, when a cash crunch has turned downright brittle for small local biotechs, a funding partner has become crucial to help push stalled drug programs forward and, in some cases survive.
Read More...

Back to Top

 

May

United Therapeutics wins FDA OK for new hypertension drug
Washington Business Journal
After hitting some roadblocks in its pulmonary arterial hypertension treatment franchise, United Therapeutics Corp. has received Food and Drug Administration approval for its first oral treatment, a coup for the Silver Spring biotech.
Read More...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 
Press Release
Vanda Pharmaceuticals Inc. announced today that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt (iloperidone) for the acute treatment of adult patients with schizophrenia.

Read More...

Clinical Data completes acquisition of Avalon Pharmaceuticals
Business Wire
Clinical Data, Inc. (Nasdaq: CLDA) today announced the completion of its acquisition of Avalon Pharmaceuticals, Inc. Clinical Data acquired Avalon through an all-stock transaction valued at approximately $10 million.
Read More... 

Back to Top

 

 April

Sanaria to begin human trials of malaria vaccine
Washington Business Review
Sanaria Inc. is working with the Path Malaria Vaccine Initiative, a Bill and Melinda Gates Foundation-funded program at a global health nonprofit based in Seattle, to test an experimental vaccine for malaria. Read More...

United Therapeutics wins FDA OK for new hypertension drug
Washington Business Journal
After hitting some roadblocks in its pulmonary arterial hypertension treatment franchise, United Therapeutics Corp. has received Food and Drug Administration approval for its first oral treatment, a coup for the Silver Spring biotech.
Read More...

Back to Top

 

 March

Neuralstem stock jumps after test result
Washington Business Journal
Shares of Neuralstem Inc. surged as much as 43 percent after the company said a positive result from the transplant of human neural stem cells into a rat could lead to treatment in humans of spinal cord injuries or ALS disease.
Read More...
 

Back to Top

February

Probiotic 'bar-code' could boost strain identification
Daily Reporter
Identifying the bacteria in a food product – be they probiotic or pathogenic – may be as easy as reading a bar-code, according to a novel technique called optical mapping. Read More... 

 Back to Top

  social media links
 

Molecule

Contact the Office | Site Map | Accessibility | Privacy Note | Refund Policy | Terms Of Use   
9700 Great Seneca Highway, Rockville, MD 20850 301-762-9214   
401 East Pratt Street, 7th Floor, Baltimore, MD 21202 410-767-0505